- Home
- BAFN vs VNRX Comparison
BAFN vs VNRX Comparison
Compare BAFN & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- VNRX
- Stock Information
- Founded
- BAFN 1999
- VNRX N/A
- Country
- BAFN United States
- VNRX United States
- Employees
- BAFN N/A
- VNRX N/A
- Industry
- BAFN Savings Institutions
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BAFN Finance
- VNRX Health Care
- Exchange
- BAFN Nasdaq
- VNRX Nasdaq
- Market Cap
- BAFN 58.8M
- VNRX 45.2M
- IPO Year
- BAFN N/A
- VNRX N/A
- Fundamental
- Price
- BAFN $14.65
- VNRX $0.47
- Analyst Decision
- BAFN
- VNRX Strong Buy
- Analyst Count
- BAFN 0
- VNRX 5
- Target Price
- BAFN N/A
- VNRX $3.75
- AVG Volume (30 Days)
- BAFN 11.4K
- VNRX 279.8K
- Earning Date
- BAFN 04-24-2025
- VNRX 05-12-2025
- Dividend Yield
- BAFN 1.98%
- VNRX N/A
- EPS Growth
- BAFN 113.18
- VNRX N/A
- EPS
- BAFN 2.34
- VNRX N/A
- Revenue
- BAFN $80,167,000.00
- VNRX $1,233,511.00
- Revenue This Year
- BAFN N/A
- VNRX $563.72
- Revenue Next Year
- BAFN N/A
- VNRX $160.43
- P/E Ratio
- BAFN $6.26
- VNRX N/A
- Revenue Growth
- BAFN 2.60
- VNRX 59.10
- 52 Week Low
- BAFN $10.40
- VNRX $0.42
- 52 Week High
- BAFN $19.75
- VNRX $1.02
- Technical
- Relative Strength Index (RSI)
- BAFN 42.79
- VNRX 39.96
- Support Level
- BAFN $13.00
- VNRX $0.45
- Resistance Level
- BAFN $16.93
- VNRX $0.54
- Average True Range (ATR)
- BAFN 0.93
- VNRX 0.06
- MACD
- BAFN 0.21
- VNRX 0.00
- Stochastic Oscillator
- BAFN 41.87
- VNRX 24.81
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.